ArticleScientific reports2026
Plasma neuropilin-1 is associated with a favorable lipid profile and insulin sensitivity in a population-based sample of 50-year-old individuals.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Membrane-bound neuropilin-1 (Nrp-1) has been implicated as a regulator of insulin resistance-related lipid metabolism, but little is known about its circulating form, soluble Nrp-1 (sNrp-1), in a metabolic context. Here we investigated the association between plasma levels of sNrp-1 and metabolic variables in 501 participants from the Prospective investigation of Obesity, Energy and Metabolism (POEM) study. Metabolic phenotyping included blood sampling, dual energy X-ray absorptiometry scan, magnetic resonance imaging for fat distribution, and a glucose tolerance test. Associations were examined using linear regression models and Spearman's rank correlation. Plasma sNrp-1 levels were inversely associated with levels of total fatty acids, triglycerides and lactate, and positively associated with markers of insulin sensitivity. In human Simpson-Golabi-Behmel Syndrome (SGBS) adipocytes, we showed that treatment with recombinant Nrp-1 reduced phosphorylation of hormone-sensitive lipase in the basal state and attenuated isoproterenol-stimulated glycerol release, a measure of total lipolytic activity. Based on these findings, we thus postulate that sNrp-1-mediated suppression of lipolysis could explain our observed association between plasma sNrp-1 and a favorable lipid profile in humans. Further studies are warranted to establish causality and to clarify the role of sNrp-1 in promoting insulin sensitivity in human adipose tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.